Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum TELESTA THERAPEUTICS INC T.TST

"Telesta Therapeutics Inc is a biopharmaceutical company. The Company is engaged in the research, development, manufacturing and commercialization of human health products and technologies."

TSX:TST - Post Discussion

TELESTA THERAPEUTICS INC > Telesta is now a phase 3 company
View:
Post by DamnYankees on Feb 02, 2016 10:41pm

Telesta is now a phase 3 company

I  think.
According to our friend John Ford of Seeking Alpha pre Adcomm fame, if the FDA were to recommend a second P3 a conservative valuation would be $150,000,000 US. I have reason to believe that this is a very reasonable assertion for a "normal" company. Yesterday Telesta was valued at half that. Telesta closed at roughly 1/10th that market cap this afternoon. A P2 green lighted to a P3, or P3a to P3b would be 50 cents US and rising, rapidly. Telesta on the same train track is 5 cents and tanking. Telesta appears to not be "normal" and is valued well outside the scope of any comparable equity. Huh
Comment by investorshub11 on Feb 02, 2016 10:43pm
Look at this guy, think he gonna get back his moneys, typical degenerate donk
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities